GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK plc has disclosed that David Redfern, President of Corporate Development, and Victoria ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...

GSK and Ionis report strong Phase 3 results for a hepatitis B drug that improved cure rates and could support regulatory filings in early 2026.

European Commission approves GSK’s recombinant zoster vaccine, Shingrix in prefilled syringe: London, UK Thursday, January 8, 2026, 09:00 Hrs [IST] GSK plc announced the Europea ...

UK pharma major GSK today announced positive results from its two pivotal Phase III trials, B-Well 1 [NCT05630807] and B-Well ...

GSK plc (NYSE:GSK) is one of the best affordable healthcare stocks to buy now. GSK plc (NYSE:GSK) announced on December 19 an ...

GSK announced it has entered a multi-year strategic collaboration agreement with Helix aiming to drive the development of ...

GlaxoSmithKline’s (GSK) Nucala (mepolizumab) has been approved by the MHRA to treat adults with uncontrolled chronic ...

Investing.com -- GSK plc (LON:GSK) on Wednesday annoucned positive phase III trial results for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B (CHB), meeting primary ...

So overall, based on the company’s predicted growth rate, higher than average dividend yield and share buyback program, I believe that GlaxoSmithKline still looks safe to buy at 1,630 pence. As well ...